Novartis licenses lipoprotein-lowering CVD drug AKCEA-APO(a)-LRx
Posted on26 Feb 2019
Comments0
Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ AKCEA-APO(a)-LRx, a treatment to reduce the risk... Read More
Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
Posted on07 Feb 2019
TagsGlemark outlicensing, global pharma licensing deal, licensing deal in pharma, outlicensing in pharma
Comments0
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced that its Swiss subsidiary, Glenmark Specialty S.A, has entered into an exclusive... Read More
Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
Daiichi Sankyo and AnHeart Therapeutics announced they have entered into a worldwide exclusive license agreement for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor,... Read More
How much is the ideal royalty payment in pharmaceutical industry?
A royalty payment is made to the legal owner of the property, patent, copyrighted work, or franchise by licensees or franchisees who... Read More
Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®
Posted on04 Oct 2018
Comments0
Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, announced a worldwide licensing agreement... Read More
Deal Insight: Daiichi Sankyo, DarwinHealth R&D agreement
Daiichi Sankyo Company, Limited and DarwinHealth announced they have entered into a research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s... Read More
AstraZeneca outlicense lung disease to Mereo BioPharma
AstraZeneca is licensing exclusive rights of AZD9668 — an oral inhibitor of an enzyme called neutrophil elastase for lung disease to Mereo... Read More
Insight on XOMA Corp and Novartis Licensing Deal
Novartis has bought the rights to Xoma’s gevokizumab. Novartis AG bagged global commercial license for Xoma Corp.’s anti-IL-1 beta monoclonal antibody gevokizumab... Read More
Samsung Bioepis and Takeda’s Co-development deal for novel biologics
Korean biosimilars manufacturer Samsung Bioepis Co Ltd. will team up with Japanese drugmaker Takeda Pharmaceutical Company to jointly develop new biologic therapies.... Read More
Insignt on Takeda and Biological E. Ltd (BE) licensing agreements for vaccines
Takeda Pharmaceutical Company (Takeda) and Biological E. Ltd (BE) have entered into a collaboration whereby two licensing agreements to expedite the development... Read More